Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fady I Malik

Showing results (31-40 of 120) with videos related to

Pageof 12
Sort By:
Circulation. Heart Failure|November 12, 2020
Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF StudyG Michael Felker, Scott D Solomon, John J V McMurray, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 14, 2019
A phase III trial of <i>tirasemtiv</i> as a potential treatment for amyotrophic lateral sclerosisJeremy M Shefner, Merit E Cudkowicz, Orla Hardiman, et al.
Muscle & Nerve|January 19, 2026
The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALSStacy A Rudnicki, Elisa Giacomelli, Katherine Herder, et al.
Journal of Veterinary Pharmacology and Therapeutics|November 16, 2022
Pharmacokinetics of a single dose of Aficamten (CK-274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat modelAshley N Sharpe, Maureen S Oldach, Joanna L Kaplan, et al.
JACC. Basic to Translational Science|May 28, 2025
Derisking Phase II Clinical Trials in Heart Failure: A Position Paper from JACC: Basic to Translational Science and the Heart Failure CollaboratoryDouglas L Mann, G Michael Felker, Ellis F Unger, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 5, 2021
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of <i>reldesemtiv</i> in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trialStacy A Rudnicki, Jinsy A Andrews, Angela Genge, et al.
The Journal of Physiology|June 28, 2019
Fast skeletal muscle troponin activator CK-2066260 increases fatigue resistance by reducing the energetic cost of muscle contractionArthur J Cheng, Darren T Hwee, Leo H Kim, et al.
Muscle & Nerve|March 18, 2014
Tirasemtiv amplifies skeletal muscle response to nerve activation in humansRichard Hansen, Khalil G Saikali, Willis Chou, et al.
JACC. Heart Failure|February 10, 2020
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HFJohn R Teerlink, Rafael Diaz, G Michael Felker, et al.
Journal of Medical Genetics|April 11, 2013
Troponin activator augments muscle force in nemaline myopathy patients with nebulin mutationsJosine Marieke de Winter, Danielle Buck, Carlos Hidalgo, et al.
Pageof 12

Showing results (31-40 of 120) with videos related to

Sort By:
Pageof 12
Circulation. Heart Failure|November 12, 2020
Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF StudyG Michael Felker, Scott D Solomon, John J V McMurray, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 14, 2019
A phase III trial of <i>tirasemtiv</i> as a potential treatment for amyotrophic lateral sclerosisJeremy M Shefner, Merit E Cudkowicz, Orla Hardiman, et al.
Muscle & Nerve|January 19, 2026
The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALSStacy A Rudnicki, Elisa Giacomelli, Katherine Herder, et al.
Journal of Veterinary Pharmacology and Therapeutics|November 16, 2022
Pharmacokinetics of a single dose of Aficamten (CK-274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat modelAshley N Sharpe, Maureen S Oldach, Joanna L Kaplan, et al.
JACC. Basic to Translational Science|May 28, 2025
Derisking Phase II Clinical Trials in Heart Failure: A Position Paper from JACC: Basic to Translational Science and the Heart Failure CollaboratoryDouglas L Mann, G Michael Felker, Ellis F Unger, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|July 5, 2021
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of <i>reldesemtiv</i> in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trialStacy A Rudnicki, Jinsy A Andrews, Angela Genge, et al.
The Journal of Physiology|June 28, 2019
Fast skeletal muscle troponin activator CK-2066260 increases fatigue resistance by reducing the energetic cost of muscle contractionArthur J Cheng, Darren T Hwee, Leo H Kim, et al.
Muscle & Nerve|March 18, 2014
Tirasemtiv amplifies skeletal muscle response to nerve activation in humansRichard Hansen, Khalil G Saikali, Willis Chou, et al.
JACC. Heart Failure|February 10, 2020
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HFJohn R Teerlink, Rafael Diaz, G Michael Felker, et al.
Journal of Medical Genetics|April 11, 2013
Troponin activator augments muscle force in nemaline myopathy patients with nebulin mutationsJosine Marieke de Winter, Danielle Buck, Carlos Hidalgo, et al.
Pageof 12